|  |  |  |  |
| --- | --- | --- | --- |
|  | [NUMPAT]-PRENOM-NOM | | |
|  |  |  | F00-Patient Information |
|  |  | **Registration-[visit date]** | |
|  |  |  | F01-Inclusion Criteria |
|  |  |  | F02-Exclusion Criteria |
|  |  |  | F03-Registration  Request |
|  |  |  | F04-Registration  Result |
|  |  |  | F05-Correction of registration criteria |
|  |  | **Baseline** | |
|  |  |  | F06-Relevant medical history |
|  |  |  | F07-Prior chemotherapy |
|  |  |  | F08-Lung Cancer Description |
|  |  |  | F09-Vital sign and Clinical Examination |
|  |  |  | F10-Laboratory tests |
|  |  | **Translational research** | |
|  |  |  | F19-Biopsy & Blood sample Baseline |
|  |  |  | F19-Biopsy & Blood sample Week 5 |
|  |  | F19-Biopsy & Blood sample at 6 month | |
|  |  | F19-Biopsy & Blood sample at progression / end of treatment. | |
|  |  |  | |
|  |  | **Cycle N° XX (repeated) (28 jours de delai)** | |
|  |  |  | F09-Vital Sign and Clinical Examination |
|  |  |  | F10-Laboratory tests |
|  |  |  | F11- Sotorasib Administration form |
|  |  |  | F11- QLQ (tous les 2 cycles) |
|  |  | **End of treatment** | |
|  |  |  | F10-Laboratory tests |
|  |  |  | F12-End of treatment-summary of care |
|  |  |  | F13-Safety visit (30 days after end of trt) |
|  |  | **Adverse Event** | |
|  |  |  | F14-Adverse Event |
|  |  | **RECIST** | |
|  |  |  | F15-RECIST Evaluation |
|  |  | **Concomitant treatment** | |
|  |  |  | F16-Concomitant treatment |
|  |  | **Follow-Up** | |
|  |  |  | F17-FU (every 12 weeks) |
|  |  |  | |
|  |  |  |  |
|  |  | **Event** | |
|  |  |  | F19-Relapse |
|  |  |  | F20-Second cancer |
|  |  |  | F21-Death |
|  |  | **End of Study** | |
|  |  |  | F22-End of Study |
|  |  | **Post étude** | |
|  |  |  | F23-LTFU |

**Schedule of Visits**